Real-time US stock event calendar and catalyst tracking for understanding upcoming market-moving announcements. Our event calendar helps you prepare for earnings releases, product launches, and other important dates.
On April 21, 2026, Merck (MRK) announced that U.S. FDA granted priority review to two supplemental biologics license applications (sBLAs) for its Keytruda (both intravenous and subcutaneous formulations) in combination with Pfizer’s antibody-drug conjugate (ADC) Padcev, for the treatment of cisplati
Pfizer Inc. (PFE) – Padcev Combination Therapy Receives FDA Priority Review for Expanded Bladder Cancer Indication - Expert Verified Trades
PFE - Stock Analysis
3711 Comments
1755 Likes
1
Jaylis
Consistent User
2 hours ago
Provides a balanced perspective on potential market outcomes.
👍 157
Reply
2
Ronesia
New Visitor
5 hours ago
Overall liquidity appears sufficient, but investors should remain mindful of potential market corrections.
👍 282
Reply
3
Raeliana
Senior Contributor
1 day ago
Trading activity suggests cautious optimism, with investors adjusting positions incrementally.
👍 251
Reply
4
Keywaun
Elite Member
1 day ago
Very helpful summary for market watchers.
👍 296
Reply
5
Zalik
Experienced Member
2 days ago
Absolute showstopper! 🎬
👍 146
Reply
© 2026 Market Analysis. All data is for informational purposes only.